Related Experiment Video

Updated: Feb 9, 2026

Electrochemical Roughening of Thin-Film Platinum Macro and Microelectrodes
08:32

Electrochemical Roughening of Thin-Film Platinum Macro and Microelectrodes

Published on: June 30, 2019

8.3K

Satraplatin: leading the new generation of oral platinum agents

Ashish Bhargava1, Ulka N Vaishampayan

  • 1Department of Medicine, Division of Hematology/Oncology, Wayne State University, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.

Expert Opinion on Investigational Drugs
|November 6, 2009
PubMed
Abstract

Insights

Satraplatin (JM-216) is an oral platinum drug with a better safety profile than cisplatin, showing promise in various cancers. Further trials are needed for FDA approval, particularly in advanced prostate cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • Satraplatin (JM-216) is a novel oral platinum analogue with an improved toxicity profile compared to cisplatin.
  • Its increased hydrophobicity suggests potential efficacy in cisplatin-resistant cancer cell lines.
  • Preclinical and clinical data support further investigation of satraplatin's pharmacology.

Purpose of the Study:

  • To review the pharmacology of satraplatin (JM-216).
  • To evaluate clinical trial data for satraplatin.
  • To assess the potential of satraplatin in treating various malignancies.

Main Methods:

  • Literature review of MEDLINE database (1985-present) using keywords 'satraplatin' or 'JM-216'.
  • Review of satraplatin abstracts presented at American Society of Clinical Oncology meetings (2007-2009).

Main Results:

  • Satraplatin demonstrates a favorable toxicity profile.
  • Clinical activity observed in breast, prostate, and lung cancers.
  • A Phase III trial in metastatic castrate-resistant prostate cancer showed improved progression-free survival but not overall survival.

Conclusions:

  • Satraplatin offers convenient oral administration and an intermittent schedule.
  • Despite clinical activity, FDA approval has not been obtained.
  • Future research should focus on trials in docetaxel-refractory metastatic castrate-resistant prostate cancer and other cisplatin-sensitive malignancies.

More Related Videos

Oral Biofilm Sampling for Microbiome Analysis in Healthy Children10:42

Oral Biofilm Sampling for Microbiome Analysis in Healthy Children

Published on: December 31, 2017

17.9K
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

14.5K

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
681
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
685
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
585
Oral Cavity01:11

Oral Cavity

The oral cavity, or the mouth, is a complex structure in humans that plays a vital role in our day-to-day lives. Its role is not only in chewing and swallowing food; it also plays a role in speech and facial expressions.
Teeth: The teeth are the hardest structures in our bodies. Humans have two sets of teeth throughout their lifetime: deciduous (baby) teeth and permanent teeth. Each tooth consists of several parts: the crown (visible part), the root (embedded in the jaw), enamel (hard outer...
3.2K
Phase-lead and Phase-lag Controllers01:22

Phase-lead and Phase-lag Controllers

Understanding the working function of different types of controllers can be illustrated with practical analogies, such as adjusting a stereo's volume equalizer. Cranking up the bass involves a phase-lead controller, which functions as a high-pass filter, while increasing the treble uses a phase-lag controller, which acts as a low-pass filter. PD controllers, similar to high-pass filters, enhance the system's response to high-frequency components. PI controllers, akin to low-pass...
574